[HTML][HTML] Resistant mechanisms to BRAF inhibitors in melanoma
JL Manzano, L Layos, C Bugés… - Annals of …, 2016 - ncbi.nlm.nih.gov
Patients with advanced melanoma have traditionally had very poor prognosis. However,
since 2011 better understanding of the biology and epidemiology of this disease has …
since 2011 better understanding of the biology and epidemiology of this disease has …
Tumor-related molecular mechanisms of oxaliplatin resistance
…, C Moutinho, L Layos, JL Manzano… - Molecular cancer …, 2015 - AACR
Oxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming
a standard in the management of this malignancy. It is also considered for the treatment of …
a standard in the management of this malignancy. It is also considered for the treatment of …
NEOHX study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach or …
…, L Lopez-Gomez, MC Galan, E Falco, JL Manzano… - 2015 - ascopubs.org
107 Background: Perioperative chemotherapy has demonstrated better OS and DFS than
surgery alone in resectable stomach or EGJ adenocarcinoma. Trastuzumab has improved OS …
surgery alone in resectable stomach or EGJ adenocarcinoma. Trastuzumab has improved OS …
[HTML][HTML] Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
…, L Sumoy, L Howells, MI James, C Iwuji, JL Manzano… - Scientific reports, 2016 - nature.com
Resistance to oxaliplatin (OXA) is a complex process affecting the outcomes of metastatic
colorectal cancer (CRC) patients treated with this drug. De-regulation of the NF-κB signalling …
colorectal cancer (CRC) patients treated with this drug. De-regulation of the NF-κB signalling …
The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies
…, MM Wang, N Karachaliou, MG Cao, JL Manzano… - Nature …, 2015 - nature.com
Resistance to RAF- and MEK-targeted therapy is a major clinical challenge 1 , 2 , 3 , 4 . RAF
and MEK inhibitors are initially but only transiently effective in some but not all patients with …
and MEK inhibitors are initially but only transiently effective in some but not all patients with …
[HTML][HTML] UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination …
…, B Massutí, A Carrato, L Layos, JL Manzano… - British journal of …, 2010 - nature.com
Background: The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase
1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer (CRC) patients …
1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer (CRC) patients …
Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma
…, E Espinosa, J Rubió, JJL López, JL Manzano… - European Journal of …, 2009 - Elsevier
This phase II clinical trial evaluated the antitumour response of Kahalalide F (KF) 650μg/m 2
given as a 1-h weekly infusion in advanced malignant melanoma patients, both untreated …
given as a 1-h weekly infusion in advanced malignant melanoma patients, both untreated …
[HTML][HTML] First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET …
…, P Escudero, F Longo-Muñoz, JL Manzano… - European Journal of …, 2017 - Elsevier
Background In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS)
metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when …
metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when …
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines
…, E Musulén, R Aguilera, JL Manzano… - Molecular cancer …, 2009 - AACR
We aimed to gain further understanding of the molecular mechanisms involved in oxaliplatin
resistance in colorectal cancer by using a proteomic approach. A 5-fold oxaliplatin-resistant …
resistance in colorectal cancer by using a proteomic approach. A 5-fold oxaliplatin-resistant …
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy
…, E Musulén, A Ginés, JL Manzano… - … journal of cancer, 2009 - Wiley Online Library
Recently, the copper efflux transporters ATP7B and ATP7A have been implicated in the
transport of and resistance to platinum drugs in breast and ovarian cancers. Because of the …
transport of and resistance to platinum drugs in breast and ovarian cancers. Because of the …